Independent medical education

Independent medical education

Blueprint Medicines may provide grants to support both accredited and non-accredited Independent Medical Education (IME), including but not limited to:

  • Programs or enduring materials produced or conducted by accredited providers to educate healthcare professionals;
  • Live learning opportunities such as grand rounds;
  • Patient, caregiver or community education programs; and
  • Written educational materials and publications.

Requests for Education

Find out more

Guiding principles

  • All requests must be submitted via the Blueprint funding portal.
  • Funding must be provided without any expectation or receipt of a benefit in exchange, other than corporate recognition.
  • All requests will be evaluated on individual merits, free from consideration of a prospective recipient’s ability to use, purchase, refer or recommend any Blueprint Medicines product, or the volume of any past or hoped for future business.
  • No funding to third-party organizations will be used to induce or reward the recipient for present, past or future support for Blueprint Medicines or use of Blueprint Medicines products.
  • Educational Grant recipients must provide an activity and budget reconciliation within 60 days after the end date of the Educational Grant activity detailing overall participation and the use of the funds. The Educational Grant recipient will be required to return any unused funds, or funds not used for the approved Educational Grant purposes.
  • Blueprint Medicines personnel may not prepare or assist with grant requests or provide direction about specific content or topics that should be included in a grant request.
  • Blueprint Medicines will not have any responsibility or control over the agenda, content, faculty, educational methods, materials and venue.

Funding may not be provided to:

  • Individual healthcare professionals; or
  • Organizations that appear on the U.S. Food and Drug Administration (FDA) debarment lists, the Office of Inspector General (OIG) U.S. Department of Health and Human Services Exclusion List, or U.S. General Services Administration (GSA) Excluded Parties List System (EPL); or
  • A wholesaler, specialty pharmacy, physician group, or other purchaser (or affiliates thereof) if the funding is offered or made in lieu of a discount or price concession, or as part of a contract negotiation or is otherwise determined to be not bona fide.
  • Educational Grants may not be provided to:
    • Directly reimburse or pay the expenses for an HCP to attend a medical conference or other educational program, unless permitted by applicable law and local or regional codes or standards. Expenses for HCP speakers, faculty and moderators of a medical education program may be included in the funding, but Blueprint may never directly pay an individual HCP or reimburse the HCP’s costs separate and apart from the Educational Grant;
    • Support capital or building expenses, personal development (e.g., leadership training, practice management training), or to support sports or entertainment related activities;
    • Directly fund meals at CME events. However, a CME provider may, at its own discretion, apply the financial support provided for a CME event to provide meals for all participants; or
    • A third party that is not the approved grant recipient.

Areas of interest

Systemic mastocytosis (SM):

Cross-specialty SM-related educational programs leveraging key conference settings within the oncology, allergy, immunology, and dermatology professional communities, as well as social media, and other media platforms, to amplify reach to multi-dimensional specialties across various practice settings (e.g., academic, hospital, and community) reaching multi-specialty audiences including allergists, immunologist, & dermatologists and providing education in the following areas of interest:

  • Recognizing the signs and symptoms of Systemic Mastocytosis (SM)
  • Screening and diagnosis of SM, including accurate sub-typing​.
  • Patient management considerations in treating Systemic Mastocytosis (SM)
  • Treatment algorithms in SM, with particular interest in treatment guidance for patients with SM with an associated hematologic neoplasm (SM-AHN)
  • New therapies and treatment options in SM, particularly for Indolent Systemic Mastocytosis (ISM) and mast cell related diseases.

     To apply, please submit your request via the Blueprint funding portal.